Print this page    •   Back to Web version of article

One Step Closer to a Vaccine

September 24, 2012

The recent RV144 vaccine trail showed a 31% reduction of HIV infections among trial participants over three years. That's good -- better than any previous trial results -- but still not good enough.

Now a paper published in Nature and presented at the AIDS Vaccine 2012 conference in Boston sheds light on why the combination of vaccines used was not more broadly effective. It had already been determined that the trail participants who did not contract HIV were producing antibodies against the V1 and V2 loops of HIV's protein shell. Genetic analysis of the virus in those who did contract HIV now shows that they were infected by strains that had mutations in the V2 loop.

It's not a home run, but for the first time we know why an HIV vaccine worked for some people but not others.

This article was provided by National Association of People With AIDS. It is a part of the publication Positive Voice. You can find this article online by typing this address into your Web browser:

General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.